Where Precision Meets Purpose - How Gemrook Laboratories is transforming women's cancer diagnostics in Nigeria.

Health Resources  /  Women's Health  /  Cancer Diagnostics

WOMEN'S HEALTH MONTH

By Gemrook Laboratories   |   Published: March 8, 2026   |   5 min read

Excellence in healthcare is not declared. It is demonstrated in every result, without compromise. On International Women's Day, we examine how Nigeria's only ISO-certified pathology laboratory is redefining what is possible for women's cancer care.

OVERVIEW

The standard Nigerian women's health deserves

Cancer does not wait for the right moment. It does not announce itself with certainty. It is found in a slide, confirmed in a molecular test, and interpreted by a team of specialists who understand that the result they produce is not data in isolation. It is the beginning of a woman's treatment journey.

At Gemrook Laboratories, that responsibility is held with absolute seriousness. As the only ISO-certified pathology laboratory in Nigeria, every test processed, every slide examined, and every report released is governed by internationally validated quality systems that most laboratories in this country have never been required to meet.

This International Women's Day, we are not simply marking a calendar date. We are reaffirming a commitment to the diagnostic precision that protects women's lives and to the standards that make that precision possible.

QUALITY STANDARDS

ISO-Certification  Nigeria’s first ISO-certified pathology laboratory — a new benchmark for diagnostic quality.

What ISO certification means for a patient

ISO certification is not a corporate distinction. It is the product of rigorous, independently audited systems that govern every aspect of laboratory operations, from sample collection and storage to test validation, result review, and ongoing quality measurement.

It means the standards Gemrook operates to are not internal estimates of quality. They are internationally benchmarked, externally verified, and continuously maintained. For a woman referred for immunohistochemistry testing, a molecular diagnostic panel, or a histopathology review, this matters enormously.

She and her oncologist need results they can trust without reservation. At Gemrook, that trust is not assumed. It is built into every protocol, every quality control check, and every specialist review before a report is released.

ISO certification in practice

ISO quality systems govern how samples are handled, how reagents are validated, how internal controls are run alongside every test, and how results are reviewed before they reach a clinician. For oncology patients, this means that ER, PR, HER2, Ki-67, and molecular results are reproducible and benchmarked against the same standards used by leading reference laboratories internationally.

BREAST CANCER DIAGNOSTICS

Immunohistochemistry and the HER2 FISH capability that exists nowhere else in Nigeria

Breast cancer remains one of the most diagnosed cancers in Nigerian women. Its management has been transformed by molecular pathology: today, treatment is shaped not just by tumour size but by the biological profile of the cancer itself, revealed through immunohistochemistry.

Gemrook's IHC panels for breast cancer cover the four markers that directly determine treatment decisions:

• ER (estrogen receptor) and PR (progesterone receptor) - determine eligibility for hormone therapy

• HER2 - determines eligibility for targeted biological agents such as trastuzumab (Herceptin)

• Ki-67 - measures tumour proliferation rate and informs prognosis and chemotherapy planning

An inaccurate result at this stage does not simply delay treatment. It misdirects it. This is why our standardised IHC protocols and strict quality controls are not procedural formalities. They are the mechanism by which a woman's treatment pathway is correctly set from the start.

On-site HER2 FISH testing: a national first

HER2 testing by immunohistochemistry can, in a proportion of cases, produce an equivocal result, a finding that is neither clearly positive nor clearly negative. In standard practice across Nigeria, this uncertainty is either left unresolved, or the patient is referred abroad for clarification. The cost, the delay, and the psychological toll of that process are significant.

Gemrook is the only laboratory in Nigeria that offers on-site HER2 FISH (Fluorescence In Situ Hybridisation) reflex testing, the gold-standard confirmatory method that resolves equivocal HER2 results with definitive molecular precision.

For the woman whose HER2 result is equivocal, this is not a marginal technical advantage. It is the difference between a confirmed treatment pathway and months of uncertainty. HER2-positive breast cancer is an aggressive subtype, but it is also one of the most treatable, when correctly identified. Gemrook has brought that answer home to Nigeria.

CERVICAL CANCER

Advanced IHC markers and the case for earlier, more accurate diagnosis

Cervical cancer is, in the truest sense, a preventable disease. A large majority of cases are caused by persistent HPV infection, and when the cellular changes driven by HPV are detected at the pre-cancerous stage, treatment is straightforward and outcomes are excellent.

The tragedy of cervical cancer in Nigeria is not that it is undetectable. It is that it is detected too late, too often.

Gemrook supports clinicians with advanced IHC markers including Ki-67 and p16, which significantly improve diagnostic accuracy in cervical pathology. Where a standard histological assessment may leave clinical uncertainty, Ki-67 and p16 co-expression provides objective, reproducible confirmation of high-grade dysplasia and invasive cervical carcinoma.

For the woman whose cervical biopsy result sits in a diagnostic grey zone, this precision is the difference between watchful waiting and prompt intervention. It is, in many cases, the difference between a curable lesion and an advanced cancer.

Ki-67 and p16 in cervical pathology

Ki-67 is a marker of cellular proliferation. p16 is overexpressed in cervical cells transformed by high-risk HPV. Together, their co-expression serves as a reliable indicator of clinically significant dysplasia, helping pathologists and clinicians distinguish lesions that require immediate intervention from those that may be safely monitored. Gemrook runs both markers within our validated IHC protocols.

PRECISION ONCOLOGY

Cancer genetics and the future of women's oncology at Gemrook

Cancer does not begin at diagnosis. For many women, the story begins in their DNA, in inherited mutations that significantly elevate lifetime risk of breast, ovarian, endometrial, and other gynaecologic cancers long before any tumour forms.

The integration of genomic insights into clinical oncology practice is no longer optional. It is foundational. And at Gemrook, our molecular diagnostics capabilities extend to both hereditary and somatic genomic characterisation.

Hereditary cancer risk

For women with a significant family history of breast or ovarian cancer, BRCA1 and BRCA2 mutation testing is a critical preventive tool. Women who carry a BRCA mutation face substantially elevated lifetime cancer risk, but they also gain access, once their status is known, to evidence-based surveillance strategies and risk-reduction options that can be genuinely lifesaving.

Somatic genomics and targeted therapy

Beyond hereditary risk, Gemrook's molecular panels support the genomic characterisation of gynaecologic malignancies including ovarian and endometrial cancers, providing the somatic mutation profiling that informs eligibility for PARP inhibitors, immune checkpoint therapy, and other precision oncology agents that are increasingly standard globally.

Every cancer is, at the molecular level, unique. Two women with clinically similar endometrial cancer may harbour entirely different somatic mutation profiles, with different implications for prognosis and therapy. Gemrook brings that level of precision to Nigerian oncology.

Questions our molecular diagnostics help clinicians answer

Is this breast cancer likely to respond to CDK4/6 inhibitors? Does this ovarian cancer carry a BRCA mutation that makes it sensitive to PARP inhibitor therapy? Does this endometrial cancer show microsatellite instability that predicts response to immune checkpoint therapy? Is this patient at risk of severe toxicity from the fluoropyrimidine chemotherapy? These are the questions that define modern oncology. Gemrook provides the answers.

OUR PEOPLE

The professionals behind the standard

Precision does not happen in the abstract. It is the product of people, specifically the pathologists, laboratory technologists, quality managers, and administrators whose expertise and discipline drive the standards Gemrook maintains every day.

On this International Women's Day, we acknowledge the exceptional women within our institution who form the backbone of our diagnostic excellence. Women who scrutinise slides with meticulous attention. Women who validate protocols. Women who audit quality systems. Women who ensure that every report that leaves Gemrook is one they would be confident to stand behind.

Their work is largely invisible to the patients whose lives depend on it. But it is present in every accurate result, every resolved diagnostic uncertainty, and every woman who begins treatment on the right pathway because the laboratory got it right.

OUR COMMITMENT

This Women's Day, and every day

We reaffirm our commitment to four principles that guide everything we do at Gemrook Laboratories:

• To elevate diagnostic medicine in Nigeria, advancing the standards of pathology and molecular diagnostics toward genuine global parity

• To uphold international quality without compromise, maintaining our ISO-certified systems with the rigour the patients we serve deserve

• To support clinicians with precision, providing accurate, timely, specialist-reviewed results that allow oncologists and gynaecologists to make confident treatment decisions

• To advance women's health with confidence, continuing to develop our capabilities in breast, cervical, ovarian, endometrial, and hereditary cancer diagnostics

Cancer does not discriminate. But access to diagnostic precision has, historically, not been equally distributed. Gemrook Laboratories exists to change that. Not through declaration, but through demonstration. Through every slide examined, every equivocal result resolved, every molecular report that gives a clinician the clarity to act.

Because when a woman's diagnosis is accurate, her treatment is empowered. And when her treatment is empowered, she has every reason to believe in what comes next.

Topics: Breast Cancer  |  Cervical Cancer  |  Ovarian Cancer  |  Genomics  |  ISO Diagnostics

Medical Disclaimer: This article is for informational and awareness purposes only. It does not constitute medical advice, diagnosis, or treatment. Patients should consult a qualified medical professional for all health-related decisions.

(c) 2026 Gemrook Laboratories. All rights reserved.  | gemrook.com